A recent preclinical study illustrated that CD70 targeted CAR-T by combining with oHSV-1 in GBM treatment, which increased the ratio of T cells to natural killer (NK) cells in TME, reducing regulatory T cells, promoting IFN-γ release, and ultimately enhancing the therapeutic effect of CD70-specific CAR-T cells [83]. This evidence concerns the gene CD70 and glioblastoma.